On February 24, 2016 Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or "The Company"), reported that data on intralesional PV-10 and co-inhibitory blockade in a melanoma model will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper)’s ("AACR") Annual Meeting 2016 on Wednesday, April 20, 2016, from 8 am to 12 Noon Central Standard Time (Filing, 8-K, Provectus Pharmaceuticals, FEB 24, 2016, View Source [SID:1234509165]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation is titled "T Cell Mediated Immunity after Combination Therapy with Intralesional PV-10 and Co-Inhibitory Blockade in a Melanoma Model." Scheduled for presentation at Section 26 of the exhibition area, the data are from a team of researchers at the H. Lee Moffitt Cancer Center in Tampa, led by Dr. Shari Pilon-Thomas.

The AACR (Free AACR Whitepaper) Annual Meeting 2016 is being held at the Ernest N. Morial Convention Center in New Orleans, Louisiana, from April 16-20, 2016.